Dihexa vs BDNF: What “10 Million Times More Potent” Actually Means

“Dihexa is 10 million times more potent than BDNF.” This claim appears in virtually every article about Dihexa (PNB-0408) and has become the central selling point for the peptide in biohacking communities. But what does it actually mean? Where does the figure come from? And does it tell us anything useful about what Dihexa might do in a living human brain? This guide unpacks the claim in full — including the important caveats most sources omit.

What Is BDNF and Why Does It Matter?

Before examining the potency comparison, it helps to understand what BDNF is and why it became the benchmark against which Dihexa is measured.

Brain-Derived Neurotrophic Factor (BDNF) is one of the most important proteins in the mammalian nervous system. It belongs to the neurotrophin family — a class of proteins that regulate the survival, development, and function of neurons. Discovered in the 1980s, BDNF has become one of the most studied molecules in neuroscience, with thousands of published papers examining its roles across virtually every aspect of brain function.

What BDNF Does in the Brain

BDNF acts primarily through the TrkB receptor (tropomyosin receptor kinase B), though it also binds with lower affinity to the p75^NTR neurotrophin receptor. Activation of TrkB triggers downstream signalling cascades — including the MAPK/ERK and PI3K/Akt pathways — that regulate neuronal survival, synaptic strength, and the expression of genes involved in plasticity.

Its most well-documented roles include:

• Long-term potentiation (LTP): BDNF is essential for the strengthening of existing synaptic connections during learning and memory consolidation. LTP in the hippocampus — the brain region most critical for declarative memory — is severely impaired in BDNF-knockout animal models.
• Neuronal survival: BDNF promotes the survival of many neuronal populations during development and helps protect neurons from damage and degeneration in adulthood. This is part of why low BDNF levels are associated with neurodegenerative diseases including Alzheimer's disease.
• Neurogenesis: BDNF supports the formation and integration of new neurons in the adult hippocampus (adult neurogenesis), a process that continues throughout life at a reduced rate.
• Synaptogenesis: BDNF promotes the formation of new synaptic connections — the process at the centre of the Dihexa comparison. It does this through TrkB-dependent signalling that influences dendritic spine growth and stabilisation.
• Mood regulation: BDNF levels in the prefrontal cortex and hippocampus are inversely associated with depression. Many antidepressants are thought to work partly by increasing BDNF expression.

In short, BDNF is a fundamental regulator of neuroplasticity — the brain's capacity to change its own structure and function. Comparing anything to BDNF is choosing an exceptionally high-bar reference point.

Natural Ways to Increase BDNF

BDNF is endogenously produced and its levels are strongly influenced by lifestyle factors. Aerobic exercise is the most well-evidenced BDNF elevator in humans, with studies showing increases after both acute bouts and chronic training. Caloric restriction, intermittent fasting, omega-3 fatty acids, and certain polyphenols (including those in dark chocolate and blueberries) show BDNF-elevating effects in preclinical and limited human research. This is relevant context: BDNF is not an exotic compound — it is a molecule the body produces and regulates constantly.

What Is Synaptogenesis?

The "10 million times" figure relates specifically to synaptogenesis — the formation of new synaptic connections between neurons. To understand why this matters, a brief explanation of what synapses are and what synaptogenesis achieves is useful.

A synapse is a specialised junction between two neurons across which chemical or electrical signals pass. Each human neuron maintains thousands of synaptic connections. The total number of synapses in the adult human brain is estimated in the hundreds of trillions. Crucially, the pattern of synaptic connections — which neurons talk to which, and how strongly — forms the physical substrate of memory, learned skills, and cognitive function.

Synaptogenesis is the process by which new synapses are formed. It is extremely active during development (most synapses form between conception and early childhood) but continues throughout adult life, particularly in the hippocampus, where new memories are encoded. As explained in our mechanism of action guide, Dihexa is believed to promote synaptogenesis by activating the HGF/c-Met receptor system — a pathway that triggers dendritic spine formation and synaptic stabilisation.

Why Synaptogenesis Matters for Cognitive Enhancement

Most conventional nootropics and cognitive enhancers operate by modulating existing neurotransmitter systems — increasing dopamine, acetylcholine, or glutamate signalling in pathways that already exist. This is sometimes described as "turning up the volume" on existing hardware.

Synaptogenesis represents a different approach: building new hardware. If a compound genuinely promotes the formation of new synaptic connections in relevant brain circuits, it theoretically offers a form of cognitive enhancement that goes beyond acute neurotransmitter modulation. This is the conceptual appeal of Dihexa and the reason the synaptogenesis comparison with BDNF became so prominent. For further context on Dihexa's broader position among cognitive-enhancement compounds, see our Dihexa vs other nootropics comparison.

The Origin of the "10 Million Times" Figure

The "10 million times more potent" claim traces primarily to research by Joseph W. Harding and colleagues at Washington State University, published in the early 2010s, examining angiotensin IV analogues and their effects on synaptogenesis. Dihexa was developed from this lineage of research as a metabolically stable small peptide derived from angiotensin IV.

The Experimental Context

In laboratory studies, researchers exposed cultured hippocampal neurons to varying concentrations of compounds and measured synaptogenesis endpoints — typically via immunostaining for synaptic proteins such as synaptophysin, PSD-95, or by counting dendritic spines under microscopy. The outcome measure was the concentration of compound required to achieve a given level of synapse formation.

When comparing Dihexa and BDNF under these conditions, the researchers found that Dihexa produced equivalent synaptogenic effects at concentrations approximately seven orders of magnitude lower than BDNF. One order of magnitude represents a tenfold difference; seven orders of magnitude equals a ten-million-fold difference. Hence the "10 million times" figure.

To put this in concrete terms: if BDNF required 1 nanomolar (1 nM) to produce measurable synaptogenesis in a cell culture assay, Dihexa would achieve the same effect at approximately 0.0000001 nM — in the sub-femtomolar range. This is an extraordinarily potent synaptogenic signal by any measure.

The Key Caveat Most Sources Omit

This comparison was made in an in vitro cell culture assay. The figure describes molar potency in a dish, not efficacy in a living animal, and certainly not efficacy in a human brain. Molar potency comparisons between compounds operating through different receptors and pathways are scientifically valid as characterisations of receptor affinity or intrinsic potency — but they cannot be linearly translated to "this is 10 million times better for your brain."

BDNF and Dihexa operate through entirely separate receptor systems (TrkB vs HGF/c-Met), are distributed differently across brain regions, cross the blood-brain barrier by different mechanisms, have different half-lives, and their downstream effects on cognition are not fully characterised even individually — let alone in comparison to each other.

How Dihexa and BDNF Differ in Mechanism

Understanding the mechanistic differences between Dihexa and BDNF helps clarify why the potency comparison, while scientifically interesting, has limited practical implications.

BDNF: TrkB-Mediated Signalling

BDNF binds to and activates TrkB receptors on neurons. TrkB activation triggers multiple intracellular signalling cascades:

• MAPK/ERK pathway: Promotes neuronal survival, differentiation, and synaptic plasticity
• PI3K/Akt pathway: Supports neuronal survival and growth
• PLCγ pathway: Regulates synaptic vesicle recycling and neurotransmitter release

These pathways collectively support what neuroscientists call "functional synaptic plasticity" — changes in how efficiently existing synapses transmit signals — as well as structural plasticity involving new synapse formation. BDNF's effects on LTP are particularly well-documented: BDNF facilitates the postsynaptic changes that make synapses more efficient over time in response to repeated activation.

Dihexa: HGF/c-Met Signalling

As detailed in our mechanism of action guide, Dihexa acts as an agonist for the hepatocyte growth factor (HGF) receptor, known as c-Met (cellular mesenchymal-epithelial transition factor). The HGF/c-Met pathway is more typically associated with liver regeneration, wound healing, and tissue repair — its role in the CNS, while real, is less extensively characterised than BDNF's TrkB signalling.

In the brain, HGF/c-Met activation has been shown to:

• Promote dendritic spine formation and branching in hippocampal neurons
• Support neuronal survival in models of ischaemia and neurotoxicity
• Enhance synaptic density as measured by synaptic protein expression
• Improve performance in spatial memory tasks in rodent models

The structural changes promoted by HGF/c-Met activation are thought to underlie Dihexa's pro-cognitive effects in animal models. Critically, this pathway does not directly overlap with BDNF's TrkB signalling. This is both a strength — it means the two can theoretically act in parallel without competing — and a limitation of the potency comparison, since comparing molar potency between compounds targeting different receptors measures different things at the molecular level.

A Useful Analogy

Consider two different construction companies: one specialises in reinforcing existing roads (BDNF strengthening existing synapses via LTP), the other in building entirely new roads (Dihexa forming new synapses via HGF/c-Met). Saying the second company needs fewer workers per kilometre of road built tells you something about their efficiency — but it doesn't tell you which is "better" for a given transport network, or whether they're even competing for the same projects.

What "Potency" Measures — And Its Limits

In pharmacology, potency refers to the amount of a compound required to produce a specific effect. It is typically expressed as the EC50 — the concentration at which 50% of the maximum effect is achieved. A compound with a lower EC50 is said to be more potent than one with a higher EC50 for the same endpoint.

Potency is a relative, endpoint-specific measure. It tells you how much of a compound you need to achieve a defined effect — nothing more. It does not directly address:

• Efficacy: The maximum effect achievable. A very potent compound may still produce a smaller maximum effect than a less potent one. (Morphine is more potent than aspirin for pain relief, but both have ceilings.)
• Selectivity: Whether the compound has effects on other targets besides the one being measured. High potency at one receptor can come with undesired effects at others.
• In vivo translation: A compound may be extremely potent in cell culture but poorly absorbed, rapidly metabolised, or unable to cross the blood-brain barrier in an intact organism.
• Clinical relevance: In vitro potency assays are designed to isolate a single variable. The brain is a complex system where hundreds of pathways interact simultaneously.
• Safety: Higher potency at a given receptor — particularly one involved in cell growth and proliferation, like c-Met — can raise safety concerns that lower-potency alternatives do not. As covered in our side effects guide, Dihexa's c-Met agonism carries potential oncogenic implications that require serious consideration.

The "10 million times" figure tells us that Dihexa is extraordinarily efficient at binding to its target and triggering synaptogenic signalling in isolated neurons. It tells us nothing about what happens after you swallow a capsule.

From Cell Culture to Living Brain: The Translation Problem

One of the most important — and most frequently glossed-over — steps in drug development is translation: demonstrating that effects observed in cell culture replicate in living animals, and then again in humans. The history of medicine is full of compounds that looked remarkable in vitro but failed in vivo.

Why Dihexa's In Vivo Evidence Is More Limited Than Often Implied

The majority of Dihexa's evidence base comes from rodent studies examining spatial memory (typically the Morris water maze) and various cognitive endpoints in animals with induced cognitive deficits. These studies do show meaningful pro-cognitive effects. As documented in our research and studies overview, Dihexa produced significant improvements in aged and scopolamine-impaired rats when compared to control groups.

However, translating these findings to humans involves several compounding uncertainties:

• Species differences in HGF/c-Met signalling: The distribution and regulation of c-Met receptors in the primate brain differ from rodents. What constitutes effective c-Met activation in rat hippocampus may not translate proportionally to human hippocampal circuits.
• Bioavailability uncertainty: Dihexa is predicted to be orally bioavailable based on its physicochemical properties, but precise oral bioavailability figures in humans have not been published. The dosage guide discusses this in detail. An impressive picomolar potency in cell culture is only clinically meaningful if sufficient concentrations actually reach the brain after oral administration.
• Model validity: Scopolamine-induced cognitive impairment in rats is a pharmacological model that mimics acetylcholine blockade, not a genuine model of Alzheimer's disease or normal human ageing. Reversing drug-induced impairment in young healthy rats is a different proposition to enhancing cognition in middle-aged humans.
• No completed human trials: As of April 2026, no completed human clinical trials for Dihexa have been published. All claims about human cognitive effects — whether positive or negative — are anecdotal. This is a fundamental limitation of the entire evidence base, regardless of how impressive the preclinical data appears.

The BDNF In Vivo Comparison

BDNF itself, despite its recognised importance in brain function, has largely failed as a direct therapeutic when administered exogenously. BDNF protein does not easily cross the blood-brain barrier, has a short half-life in the body, and requires sophisticated delivery systems for CNS applications. This is part of why drugs that upregulate endogenous BDNF expression (such as exercise, antidepressants, and certain dietary compounds) are the practical focus of BDNF-based interventions rather than BDNF protein itself.

This context is important: even though BDNF requires 10 million times higher concentrations to produce synaptogenesis in a dish, administering BDNF protein to a human is not the same as that number implies. The in vitro potency difference between Dihexa and BDNF does not mean Dihexa would outperform the effects of BDNF in a living brain by that same factor.

Dihexa's Role in Neuroplasticity: What the Research Actually Suggests

Setting aside the potency comparison, the more relevant question is: what does the preclinical evidence genuinely suggest about Dihexa's neuroplasticity effects?

Dendritic Spine Density

Several studies examining Dihexa and related angiotensin IV analogues report increases in dendritic spine density in hippocampal neurons following treatment. Dendritic spines are small protrusions on neuronal dendrites that form the postsynaptic component of most excitatory synapses. Greater spine density correlates with greater synaptic connectivity. In rodent models, Dihexa treatment produced measurable increases in spine density alongside cognitive improvements, suggesting the structural changes are behaviourally relevant.

Long-Term Effects

One of the distinctive features reported in the original Dihexa literature is that effects appeared to persist for extended periods after treatment cessation — weeks to months in animal studies. This is consistent with a mechanism involving structural changes (new synapse formation) rather than transient neurotransmitter modulation. If this translates to humans, it would be a significant differentiator from most nootropic compounds, whose effects cease when the compound clears the system.

Dihexa's exceptionally long half-life of approximately 12 days (compared to hours for most peptides) contributes to extended duration of action. As detailed in the dosage and pharmacokinetics guide, this long half-life is one reason researchers approach Dihexa dosing conservatively.

Relevance to Alzheimer's and Neurodegeneration

The HGF/c-Met pathway is disrupted in Alzheimer's disease, and restoring its signalling is one of the therapeutic hypotheses that drove Athira Pharma's development of fosgonimeton — the next-generation Dihexa derivative examined in human clinical trials. As covered in our fosgonimeton and Athira Pharma guide and our Alzheimer's research overview, the HGF/c-Met pathway remains a scientifically credible target for cognitive decline, even as the specific clinical programme has faced significant challenges.

The Athira Controversy and What It Means for the Evidence Base

Any accurate discussion of Dihexa's "10 million times" claim in 2026 must address the Athira controversy, which materially affects the strength of the evidence underpinning the claim.

The Retraction

In 2025, a foundational 2014 study by Leen Kawas and colleagues examining Dihexa's synaptogenic properties was retracted following findings of image manipulation. Kawas, who later became CEO of Athira Pharma, had her PhD revoked by Washington State University. Athira Pharma subsequently paid a $4.07 million settlement to resolve allegations of data falsification connected to this research.

This retraction is significant. It does not necessarily mean Dihexa has no synaptogenic effects — the HGF/c-Met pathway's involvement in synaptogenesis is supported by multiple independent lines of research not connected to Kawas's work. But it does mean that at least some portion of the specific quantitative evidence for Dihexa's synaptogenic potency — potentially including data underlying the "10 million times" figure — rests on research that has been found to contain manipulated data.

What Remains Credible

The fundamental biology of HGF/c-Met signalling in neuroplasticity is well-established and does not depend on the retracted papers. Numerous independent research groups have documented c-Met's role in dendritic spine formation, synaptic plasticity, and hippocampal function. What is less certain, following the retraction, is the specific quantitative characterisation of Dihexa's potency relative to BDNF. Researchers and self-experimenters should weight this uncertainty appropriately rather than treating the "10 million times" figure as a settled fact.

For a thorough review of the available research and its limitations, see our Dihexa research and studies overview.

Practical Implications for Researchers

For those approaching Dihexa as a research compound, understanding the BDNF comparison properly leads to several practical conclusions:

1. Potency Does Not Equal Dose Guidance

The "10 million times" figure might tempt some to reason that Dihexa should be used at extremely low doses. This logic does not follow. The in vitro potency comparison establishes receptor binding affinity in cell culture — not the dose required to achieve measurable cognitive effects in a living human, which depends on bioavailability, distribution, metabolism, and a host of other pharmacokinetic variables. Community protocols documented in our dosage guide typically cluster around 10–20mg daily, with no dose-response data in humans to validate any specific amount.

2. Potency Amplifies Safety Concerns

If Dihexa is genuinely a highly potent c-Met agonist, this is not only good news. The c-Met receptor pathway, when chronically overactivated, is associated with cellular proliferation and has proto-oncogenic properties. High intrinsic potency at c-Met means even low Dihexa concentrations could produce significant downstream signalling. Combined with the compound's long half-life and accumulation potential, this strengthens the case for caution rather than providing reassurance. The full implications are explored in our side effects and risks guide.

3. The Comparison Is a Starting Point, Not a Conclusion

The BDNF potency comparison was a useful finding in the context of identifying angiotensin IV analogues as candidates for further development. It established that HGF/c-Met signalling can drive synaptogenesis at extremely low compound concentrations — a promising pharmacological property. It was never intended to serve as evidence that Dihexa outperforms endogenous neurotrophins in a living human brain, and presenting it that way in marketing or community discussions oversimplifies what the science actually shows.

4. Combining with BDNF-Elevating Approaches

Because Dihexa and BDNF work through separate pathways, they are not in direct competition. Some researchers hypothesise that combining Dihexa's structural synaptogenic effects with interventions that elevate endogenous BDNF (exercise, certain peptides such as Semax, dietary interventions) might produce complementary neuroplasticity effects. This is the mechanistic basis for several of the stacks examined in our Dihexa stacking guide. The rationale is plausible but unstudied in humans.

BDNF-Boosting Approaches: How They Compare

Given the limitations of both Dihexa and BDNF as direct treatments, it is worth briefly contextualising what actually elevates BDNF and neuroplasticity markers in humans with meaningful evidence:

This table illustrates an important point for researchers: the interventions with the strongest human evidence for neuroplasticity benefits are lifestyle-based or have been clinically validated, not the most pharmacologically potent compounds in cell culture assays. This does not mean Dihexa lacks promise — it means the current evidence warrants appropriate humility about what is and is not established.

Summary: What the Comparison Tells Us and What It Doesn't

The "10 million times more potent than BDNF" claim about Dihexa is simultaneously a genuine scientific finding and a regularly misrepresented one. Here is a clear summary of what the comparison does and does not support:

Frequently Asked Questions